GROWTH HORMONE THERAPY FOLLOW-UP PROGRAMME IN PAEDIATRICS PATIENTS

Del Estal Jiménez J, Martín Marqués M, López Broseta P, De Dios López A, Jornet Montaña S, Sánchez Parada L, Canela Subirat M, Canadell Villarrasa L.
Hospital Universitari Joan XXIII, Pharmacy Service, Tarragona, Spain

Objectives

Adequate evaluation of description and monitoring of pediatric patients treated with growth hormones.

Study design

Retrospective and observational study was performed on patients that initiated growth hormone treatment between years 2009 and 2016. The data we used was obtained from patient's records and collected following the Ministry of Health recommendations:

Dose of the drug	**Heigth and weight**
Weight)	**Insulin growth (IGF-I)**
Value	**Growth rate**
Bone age	**Adult height prediction**
Pubertal study	**Growth chart**
Adverse effects	**Adherence to treatment**

Results

32 patients
(10±3 years old)
56% children

Diagnosis
- Classic Growth Hormone Deficiency in 90 %
- Intrauterine Growth Retardation in 10 %

All of them had data on **height, weight and growth rate** and **growth chart** was not present in any of them.

Adult height prediction was only present in 3 % of cases and **pubertal study** in 75 % of cases.

Bone age was studied in 87 % of cases and **Insulin growth factor** was determined after 12 months of treatment in 68 % of cases.

Initial dosage ✓100%

Next dosage ✘18%

Adherence 90%

Adverse effects 12%



Hyperinsulinaemia, Myalgia and Cephalea.

Conclusions

Treatment monitoring does not comply with stablished criteria. There is a need of **Pharmaceutical Care** in order to guarantee optimal monitoring and security of treatment.

HJ23
Hospital Universitari **Joan XXIII**
ICS Camp de Tarragona

Hospital pharmacist – Show us what you can do
23rd Congress of the EAHP
21 – 23 March 2018, Gothenburg, Sweden

jorgedelestal.hj23.ics@gencat.cat

4CPS-044